Last reviewed · How we verify
WS016
WS016 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
WS016 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | WS016 |
|---|---|
| Sponsor | Waterstone Pharmaceutical (Wuhan) Co., LTD. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, WS016 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia (PHASE3)
- The Safety and Tolerability of WS016 in Healthy Chinese Volunteers (PHASE1)
- A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |